Halozyme Therapeutics (NASDAQ:HALO) Price Target Raised to $53.00

Halozyme Therapeutics (NASDAQ:HALO) had its target price lifted by Piper Sandler from $52.00 to $53.00 in a research report report published on Friday,Benzinga reports. The firm currently has a neutral rating on the biopharmaceutical company’s stock.

A number of other brokerages have also issued reports on HALO. Cowen reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. JMP Securities raised their target price on Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a research note on Friday, November 1st. HC Wainwright lifted their target price on Halozyme Therapeutics from $68.00 to $70.00 and gave the stock a “buy” rating in a report on Friday. Wells Fargo & Company downgraded shares of Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and upped their price target for the company from $58.00 to $62.00 in a report on Monday, October 7th. Finally, JPMorgan Chase & Co. cut shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and lifted their price objective for the stock from $52.00 to $57.00 in a research note on Thursday, September 19th. Four equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $61.44.

Halozyme Therapeutics Trading Down 1.8 %

Shares of NASDAQ:HALO opened at $52.80 on Friday. The company has a 50 day moving average of $50.14 and a 200-day moving average of $54.02. The company has a current ratio of 10.36, a quick ratio of 9.15 and a debt-to-equity ratio of 3.32. The firm has a market cap of $6.72 billion, a P/E ratio of 17.48, a P/E/G ratio of 0.44 and a beta of 1.24. Halozyme Therapeutics has a twelve month low of $33.15 and a twelve month high of $65.53.

Insider Transactions at Halozyme Therapeutics

In other news, SVP Michael J. Labarre sold 10,000 shares of the firm’s stock in a transaction on Wednesday, October 16th. The stock was sold at an average price of $53.26, for a total value of $532,600.00. Following the completion of the sale, the senior vice president now owns 173,756 shares of the company’s stock, valued at $9,254,244.56. This trade represents a 5.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 2.40% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Halozyme Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of HALO. RPg Family Wealth Advisory LLC purchased a new stake in shares of Halozyme Therapeutics in the third quarter worth approximately $1,886,000. Segall Bryant & Hamill LLC increased its stake in Halozyme Therapeutics by 16.3% in the 3rd quarter. Segall Bryant & Hamill LLC now owns 355,176 shares of the biopharmaceutical company’s stock valued at $20,330,000 after buying an additional 49,856 shares during the period. Retirement Systems of Alabama lifted its position in Halozyme Therapeutics by 23.5% in the 3rd quarter. Retirement Systems of Alabama now owns 389,268 shares of the biopharmaceutical company’s stock worth $22,282,000 after buying an additional 74,173 shares in the last quarter. Creative Planning boosted its stake in shares of Halozyme Therapeutics by 43.2% during the 2nd quarter. Creative Planning now owns 37,291 shares of the biopharmaceutical company’s stock valued at $1,953,000 after buying an additional 11,249 shares during the period. Finally, South Street Advisors LLC purchased a new position in shares of Halozyme Therapeutics during the 3rd quarter valued at $9,812,000. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.